Denisk, all due respect, there a lot of angles to this story, and many things at play, from legal to scientific to business. I don't think it would be a bad idea to discuss what happened to a three year trial funded in part by Amarin.
Likewise, if other people want to focus on other threads (stock buybacks, Denner, legal issues) I'm completely fine with it, and in fact am happy to see it.
Denisk... "Mitigate was never intended as a clinical trial to reveal additional positive medical results for using Vascepa/ Vazkepa was only done to promote the distribution and sale of Vascepa to KP customers and patients.Total waste of time to talk about it." ...WRONG!!
IMO KP cares little to nothing about the distribution and sales of Vascepa to their customers...except as this might relate to KP's saving money by preserving the health of their customers.
Amarin, which provided the Vascepa to KP for for the study, as well as we investors, deserve to know the reason for it being stopped...and I am confident that the results will become known soon.
Market Data 
Markets 
AI
